Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Martin

Showing results (201-210 of 278) with videos related to

Pageof 28
Sort By:
Journal of Clinical Microbiology|May 9, 2014
Comparative evaluation of 11 commercialized rapid diagnostic tests for detecting Trypanosoma cruzi antibodies in serum banks in areas of endemicity and nonendemicityClaudia L Sánchez-Camargo, Pedro Albajar-Viñas, Patricia P Wilkins, et al.
Breast Cancer Research : BCR|April 19, 2015
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2012
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acidMiguel Martin, Richard Bell, Hugues Bourgeois, et al.
European Journal of Cancer (Oxford, England : 1990)|January 20, 2024
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancerSara M Tolaney, Valentina Guarneri, Jae Hong Seo, et al.
Breast Cancer Research : BCR|April 15, 2014
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trialMiguel Martin, Jan C Brase, Lourdes Calvo, et al.
Breast Cancer Research and Treatment|August 20, 2021
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded populationMichelino De Laurentiis, Simona Borstnar, Mario Campone, et al.
JCO Global Oncology|February 2, 2021
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in OncologyConcetta Elisa Onesti, Marco Tagliamento, Giuseppe Curigliano, et al.
Molecular Cell|November 3, 2022
Reversal of mitochondrial malate dehydrogenase 2 enables anaplerosis via redox rescue in respiration-deficient cellsPatricia Altea-Manzano, Anke Vandekeere, Joy Edwards-Hicks, et al.
Pharmaceutics|March 6, 2021
Chimeric Drug Design with a Noncharged Carrier for Mitochondrial DeliveryConsuelo Ripoll, Pilar Herrero-Foncubierta, Virginia Puente-Muñoz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab ResistanceHoward M Stern, Humphrey Gardner, Tomasz Burzykowski, et al.
Pageof 28

Showing results (201-210 of 278) with videos related to

Sort By:
Pageof 28
Journal of Clinical Microbiology|May 9, 2014
Comparative evaluation of 11 commercialized rapid diagnostic tests for detecting Trypanosoma cruzi antibodies in serum banks in areas of endemicity and nonendemicityClaudia L Sánchez-Camargo, Pedro Albajar-Viñas, Patricia P Wilkins, et al.
Breast Cancer Research : BCR|April 19, 2015
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyKathrin Strasser-Weippl, Nora Horick, Ian E Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2012
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acidMiguel Martin, Richard Bell, Hugues Bourgeois, et al.
European Journal of Cancer (Oxford, England : 1990)|January 20, 2024
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancerSara M Tolaney, Valentina Guarneri, Jae Hong Seo, et al.
Breast Cancer Research : BCR|April 15, 2014
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trialMiguel Martin, Jan C Brase, Lourdes Calvo, et al.
Breast Cancer Research and Treatment|August 20, 2021
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded populationMichelino De Laurentiis, Simona Borstnar, Mario Campone, et al.
JCO Global Oncology|February 2, 2021
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in OncologyConcetta Elisa Onesti, Marco Tagliamento, Giuseppe Curigliano, et al.
Molecular Cell|November 3, 2022
Reversal of mitochondrial malate dehydrogenase 2 enables anaplerosis via redox rescue in respiration-deficient cellsPatricia Altea-Manzano, Anke Vandekeere, Joy Edwards-Hicks, et al.
Pharmaceutics|March 6, 2021
Chimeric Drug Design with a Noncharged Carrier for Mitochondrial DeliveryConsuelo Ripoll, Pilar Herrero-Foncubierta, Virginia Puente-Muñoz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2015
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab ResistanceHoward M Stern, Humphrey Gardner, Tomasz Burzykowski, et al.
Pageof 28